{"id":627750,"date":"2022-11-29T16:18:01","date_gmt":"2022-11-29T16:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=627750"},"modified":"2022-11-29T16:18:01","modified_gmt":"2022-11-29T16:18:01","slug":"covid19-competitive-landscape-report-2022-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/covid19-competitive-landscape-report-2022-by-delveinsight_627750.html","title":{"rendered":"COVID-19 Competitive landscape Report 2022 by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1669722414.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"COVID-19 Competitive landscape Report 2022 by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1669722414.png\" alt=\"COVID-19 Competitive landscape Report 2022 by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>COVID-19 Competitive landscape<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">COVID-19 pipeline constitutes 420+ key companies continuously working towards developing 520+ COVID-19 treatment therapies, analyzes DelveInsight<\/div>\n<p style=\"text-align: justify;\">COVID-19 is the result of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first isolated and identified in patients who were exposed at a seafood market in Wuhan City, Hubei Province, China in December 2019. Similar to findings related to SARS-CoV and Middle East respiratory syndrome coronavirus, SARS-CoV-2 is believed to cross species to initiate primary human infections; it is now spread primarily by human-to-human transmission.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsights, &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>COVID-19<\/strong><strong> Competitive landscape, 2022<\/strong><\/a>&rdquo; report provides comprehensive insights about 420+ companies and COVID-19 drugs in COVID-19 Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/7a30904b0f04bfec14e977e6bd9f62fb.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about the <\/strong><strong>COVID-19<\/strong><strong> Competitive landscape report, click here: <\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">COVID-19 Therapeutic Landscape<\/a> <\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <\/strong><strong>COVID-19<\/strong><strong> Competitive landscape report:<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Leading COVID-19 Companies working in the market are Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Valneva, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science,S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Sound Pharmaceuticals, Sorrento Therapeutics and Others.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Key COVID-19 therapies in various stages of development include SKYCovione, Sotrovimab, Sargramostim, Tradipitant, XAV-19, MAD0004J08, RESP301, Niclosamide, Sinapultide, MAS-825, Maraviroc, Abivertinib, Ebselen, Duvelisib, TCB008 and Others.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>In April 2022, Direct Biologics, announced that the US Food and Drug Administration has awarded their EV drug product ExoFlo with a regenerative Medicine Advanced Therapy designation for the treatment of Acute Respiratory Distress Syndrome associated with COVID-19.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about the <\/strong><strong>COVID-19<\/strong><strong> therapeutic report, click here: <\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/covid-19-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">COVID-19 Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s <\/strong><strong>COVID-19<\/strong><strong> Report covers around 520+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Assessment by COVID-19 Product Type<\/li>\n<li>Assessment by Stage and Product Type of COVID-19<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration of COVID-19<\/li>\n<li>Assessment by COVID-19 Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type of COVID-19<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging <\/strong><strong>COVID-19<\/strong><strong> Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the COVID-19 therapies are Sotrovimab, SKYCovione and Many Others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further <\/strong><strong>COVID-19<\/strong><strong> product details are provided in the report. Download the <\/strong><strong>COVID-19<\/strong><strong> Pipeline report to learn more about the emerging <\/strong><strong>COVID-19<\/strong><strong> therapies at<\/strong>: <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/covid-19-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">COVID-19 Competitive Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key companies in the COVID-19 Therapeutics Market:<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the COVID-19 Companies working in the market are Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Valneva, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science,S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Sound Pharmaceuticals, Sorrento Therapeutics and Others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report to know in detail about the recent developments&nbsp;and&nbsp;<\/strong><strong>Advancements in <\/strong><strong>COVID-19<\/strong><strong> clinical trials<\/strong> &#8211; <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/covid-19-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">COVID-19 drugs and FDA Approvals<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">1. COVID-19 Pipeline Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. COVID-19 Pipeline Report Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. COVID-19 Pipeline: Overview<\/p>\n<p style=\"text-align: justify;\">4. Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. COVID-19 Clinical Trial Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. COVID-19 Pipeline: Late Stage Products (Pre-registration)<\/p>\n<p style=\"text-align: justify;\">7. COVID-19 Pipeline: Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">8. COVID-19 Pipeline: Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">9. COVID-19 Pipeline: Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">10.&nbsp; COVID-19 Pipeline Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products in the COVID-19 Pipeline<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Key COVID-19 Companies<\/p>\n<p style=\"text-align: justify;\">14. Key Products in the COVID-19 Pipeline<\/p>\n<p style=\"text-align: justify;\">15. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16. COVID-19 Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=covid19-competitive-landscape-report-2022-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=covid19-competitive-landscape-report-2022-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>COVID-19 Competitive landscape COVID-19 pipeline constitutes 420+ key companies continuously working towards developing 520+ COVID-19 treatment therapies, analyzes DelveInsight COVID-19 is the result of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first isolated and identified in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/covid19-competitive-landscape-report-2022-by-delveinsight_627750.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-627750","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/627750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=627750"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/627750\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=627750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=627750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=627750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}